Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated:  7/30/2015
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated: 7/30/2015
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated:  7/30/2015
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated: 7/30/2015
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated:  7/30/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated: 7/30/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated:  7/30/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
ADAM-Afatinib Diarrhea Assessment and Management
A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)
Status: Enrolling
Updated: 7/30/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Research Site
mi
from
Seongnam,
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Research Site
mi
from
Seongnam,
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Click here to add this to my saved trials
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers
Status: Enrolling
Updated:  8/3/2015
University of Rochester, Dept. Radiation Oncology
mi
from
Rochester, NY
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers
Status: Enrolling
Updated: 8/3/2015
University of Rochester, Dept. Radiation Oncology
mi
from
Rochester, NY
Click here to add this to my saved trials
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated:  8/7/2015
Massachusetts General Hospital
mi
from
Boston, MA
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated: 8/7/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated:  8/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated: 8/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated:  8/7/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated: 8/7/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated:  8/7/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Detecting EGFR T790M Mutations From Circulating Tumor Cells
Status: Enrolling
Updated: 8/7/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/11/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2015
Southwest Oncology Group
mi
from
San Antonio, TX
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2015
Southwest Oncology Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated:  8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated: 8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1220.48.0008 Boehringer Ingelheim Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1160.189.10250 Boehringer Ingelheim Investigational Site
mi
from
Beverly Hills, CA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1160.189.10250 Boehringer Ingelheim Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1200.22.4 Boehringer Ingelheim Investigational Site
mi
from
Mission Hills, CA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1200.22.4 Boehringer Ingelheim Investigational Site
mi
from
Mission Hills, CA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
205.452.01148 Boehringer Ingelheim Investigational Site
mi
from
Orange, CA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
205.452.01148 Boehringer Ingelheim Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1199.14.1199 Boehringer Ingelheim Investigational Site
mi
from
North Miami Beach, FL
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1199.14.1199 Boehringer Ingelheim Investigational Site
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1200.75.10038 Boehringer Ingelheim Investigational Site
mi
from
Bethesda, MD
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1200.75.10038 Boehringer Ingelheim Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
205.440.1003 Boehringer Ingelheim Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1218.64.10004 Boehringer Ingelheim Investigational Site
mi
from
Flint, MI
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1218.64.10004 Boehringer Ingelheim Investigational Site
mi
from
Flint, MI
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1200.32.2603 Boehringer Ingelheim Investigational Site
mi
from
Rochester, NY
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1200.32.2603 Boehringer Ingelheim Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
205.452.01293 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, NY
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
205.452.01293 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1230.14.10009 Boehringer Ingelheim Investigational Site
mi
from
Valhalla, NY
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1230.14.10009 Boehringer Ingelheim Investigational Site
mi
from
Valhalla, NY
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1199.14.1174 Boehringer Ingelheim Investigational Site
mi
from
Canton, OH
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1199.14.1174 Boehringer Ingelheim Investigational Site
mi
from
Canton, OH
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1321.3.10047 Boehringer Ingelheim Investigational Site
mi
from
Wynnewood, PA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1321.3.10047 Boehringer Ingelheim Investigational Site
mi
from
Wynnewood, PA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1245.25.10140 Boehringer Ingelheim Investigational Site
mi
from
Mt. Pleasant, SC
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1245.25.10140 Boehringer Ingelheim Investigational Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1220.48.0042 Boehringer Ingelheim Investigational Site
mi
from
Fairfax, VA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1220.48.0042 Boehringer Ingelheim Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1245.36.10023 Boehringer Ingelheim Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1199.14.1158 Boehringer Ingelheim Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  8/12/2015
1200.22.88604 Taichung Veterans General Hospital
mi
from
Taichung,
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 8/12/2015
1200.22.88604 Taichung Veterans General Hospital
mi
from
Taichung,
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Cedars Sinai
mi
from
Los Angeles, CA
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Cedars Sinai
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
ITOR Cancer Center of North Carolina
mi
from
Greenville, SC
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
ITOR Cancer Center of North Carolina
mi
from
Greenville, SC
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
NYU Cancer Institute
mi
from
New York, NY
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Hospital Universitari Vall d'Hebron
mi
from
Barcelona,
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Hospital Universitari Vall d'Hebron
mi
from
Barcelona,
Click here to add this to my saved trials
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  8/14/2015
Lovelace Medical Group
mi
from
Albuquerque, NM
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 8/14/2015
Lovelace Medical Group
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  8/14/2015
Hematology Oncology Associates NM
mi
from
Albuquerque, NM
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 8/14/2015
Hematology Oncology Associates NM
mi
from
Albuquerque, NM
Click here to add this to my saved trials